The 8 linked references in paper D. Naskhletashvili R., V. Gorbunova A., A. Bekyashev Kh., L. Demidov V., G. Kharkevich Yu., S. Banov M., I. Samoylenko V., K. Baryshnikov А., K. Orlova V., I. Utyashev А., N. Petenko N., I. Markina G., E. Moskvina A., S. Medvedev V., Д. Насхлеташвили Р., В. Горбунова А., А. Бекяшев Х., Л. Демидов В., Г. Харкевич Ю., С. Банов М., И. Самойленко В., К. Барышников А., К. Орлова В., И. Утяшев А., Н. Петенко Н., И. Маркина Г., Е. Москвина А., С. Медведев В. (2017) “ВЕМУРАФЕНИБ В ЛЕЧЕНИИ БОЛЬНЫХ МЕЛАНОМОЙ С МЕТАСТАЗАМИ В ГОЛОВНОЙ МОЗГ // VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES” / spz:neicon:ogsh:y:2016:i:4:p:30-34

  1. Davies M., Liu P., McIntyre S. et al. Prognostic factors for survival in melanoma patients with bran metastases. Cancer 2011;117(8):1687–96. DOI: 10.1002/cncr.25634.
  2. Eigentler T., Figl A., Krex D. et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011;117(8):1697–703. DOI: 10.1002/cncr.25631.
  3. Atkins M., Sosman J., Agarwala S. et al. Temozolomide, thalidomide and whole brain radiation therapy for patients with brain metastases from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008;113(8):2139–45. DOI: 10.1002/cncr.23805.
  4. Long G.V., Margolin K.A. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book 2013;393–8. DOI: 10.1200/EdBook_AM.2013.33.393.
  5. Jakob J.A., Bassett R.L. Jr, Ng C.S. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014–23. DOI: 10.1002/cncr.26724.
  6. Dummer R., Goldinger S., Turtschietal C. Vemurafenib in patients with BRAF V600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer 2014;50(3):611–21. DOI: 10.1016/j.ejca.2013.11.002.
  7. Larkin J., DelVecchio M., Ascierto P. et al. Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014;15(4):436–44. DOI: 10.1016/S1470-2045(14)70051-8.
  8. Berghoff A.S., Preusser M. The future of targeted therapies for brain metastases. Future Oncol 2015;11(16):2315–27. DOI: 10.2217/fon.15.127